Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022

Vandana Singh
1 min read
0
In this article:

  • Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19.

  • The data were presented at the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)–World Health Organization (WHO) Virtual Conference 2021.

  • Preclinical data showed potent inhibition of SARS-CoV-2 replication and was retained against proteases from SARS-CoV-2 variants.

  • Additionally, EDP-235 was shown to have potent antiviral activity across other human coronaviruses.

  • EDP-235 showed good human Caco-2 cell permeability and a low plasma clearance in human liver microsomes. EDP-235 had favorable in vivo penetration into multiple target tissues, including lung, kidney, liver, and heart.

  • Enanta has completed IND-enabling preclinical studies of EDP-235 and plans to advance the candidate into the clinic in early 2022.

  • Related: Enanta To Discontinue Internal Development Of NASH Candidates.

  • Price Action: ENTA shares are up 0.03% at $68.78 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories